Edition:
India

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

1.40USD
17 Jun 2019
Change (% chg)

-- (--)
Prev Close
$1.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
12,550
52-wk High
$13.39
52-wk Low
$1.10

Latest Key Developments (Source: Significant Developments)

Summit Therapeutics enters exclusive licence agreement with Eurofarma Laboratórios
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Summit Therapeutics Plc ::SUMMIT THERAPEUTICS PLC HAS ENTERED INTO AN EXCLUSIVE LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA LABORATÓRIOS SA.AGREEMENT GRANTS EUROFARMA LABORATÓRIOS SA RIGHTS IN LATIN AMERICA TO SUMMIT'S PRECISION ANTIBIOTIC RIDINILAZOLE IN DEVELOPMENT FOR THE TREATMENT OF CDI.SUMMIT RETAINS COMMERCIALISATION RIGHTS IN ALL OTHER COUNTRIES.RIDINILAZOLE IS A TARGETED ANTIBIOTIC THAT HAS THE POTENTIAL AS A FRONTLINE THERAPY TO TREAT INITIAL INFECTION AND PRESERVE PATIENTS' MICROBIOMES TO REDUCE THE RATE OF RECURRENT CDI .  Full Article

Summit highlights DMD biomarker phase 2 clinical trial data in presentations at 22nd WMS Congress
Wednesday, 4 Oct 2017 

Oct 4 (Reuters) - Summit Therapeutics Plc : :Summit highlights DMD biomarker validation data and phase 2 clinical trial baseline characteristics in presentations at 22nd WMS Congress.Summit highlights DMD biomarker validation data and phase 2 clinical trial baseline characteristics in presentations at 22nd WMS congress.Summit Therapeutics Plc - ‍expect to report first 24-week biopsy, MRI and functional data from phaseout DMD in Q1 2018​.Summit Therapeutics Plc - ‍top-line data from complete 48-week clinical trial expected in Q3 2018​.  Full Article

Summit announces positive top-line data from an exploratory phase 2 supporting Ridinilazole
Tuesday, 5 Sep 2017 

Sept 5 (Reuters) - Summit Therapeutics Plc :Summit announces positive top-line data from an exploratory phase 2 clinical trial supporting Ridinilazole as a highly selective antibiotic for the treatment of CDI.Secondary endpoint of SCR, was achieved in 7 of 14 Ridinilazole treated patients and six of 13 fidaxomicin treated patients.Summit Therapeutics Plc - look forward to initiating phase 3 clinical trials in first half of 2018.  Full Article

Summit Therapeutics reports financial results for Q2 ended July 31 2017
Thursday, 31 Aug 2017 

Aug 31 (Reuters) - Summit Therapeutics Plc :Summit Therapeutics reports financial results for the second quarter and half year ended July 31 2017 and operational progress.Summit Therapeutics Plc - ‍revenue was £18.9 million for three months ended 31 July 2017 compared to £nil for three months ended 31 July 2016​.Summit Therapeutics Plc - ‍total comprehensive income for three months ended 31 july 2017 was £10.9 million with a basic earnings per share of 18 pence​.  Full Article

Bangladesh's Summit, Japan's JERA to invest $500 million in Cox's Bazar energy project

SINGAPORE/DHAKA A company controlled by Bangladesh's Summit Group said on Wednesday it had signed a memorandum of understanding (MOU) with Japan's JERA Asia to develop energy infrastructure including port facilities in the Matarbari area in Cox's Bazar.

No consensus analysis data available.